Skip to main content
. 2014 May 8;14:326. doi: 10.1186/1471-2407-14-326

Table 1.

Cohort description

Variables n %
ER
 
 
Negative
14
51.9%
Positive
9
33.3%
Unknown
4
14.8%
PR
 
 
Negative
18
66.7%
Positive
5
18.5%
Unknown
4
14.8%
Run-in Treatment
 
 
Trastuzumab
17
63.0%
Nab-paclitaxel
10
37.0%
Response
 
 
PathCR
13
48.1%
No PathCR
10
37.0%
Unknown 4 14.8%